Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Oncology (Williston Park). 2010 Jan;24(1):29-35.
Lung cancer in "never-smokers" constitutes only a small proportion of patients with lung cancer. Nevertheless, the topic has recently attracted a good deal of attention. Initially this was due to the fact that never-smokers with lung cancer had better outcomes with epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitors, compared to tobacco smokers with lung cancer. More recently the identification of molecular changes unique to lung cancer in never-smokers has generated further interest in this disease. These findings have the potential to enhance our knowledge of lung cancer biology and lead to the development of new, more effective treatments for lung cancer. In this review, we summarize the existing body of knowledge on lung cancer in never-smokers.
“不吸烟者”中的肺癌仅占肺癌患者的一小部分。然而,这个话题最近引起了广泛关注。最初,这是因为与吸烟的肺癌患者相比,患有肺癌的不吸烟者使用表皮生长因子受体酪氨酸激酶(EGFR-TK)抑制剂的效果更好。最近,在不吸烟者的肺癌中发现了独特的分子变化,这进一步引起了人们对这种疾病的兴趣。这些发现有可能增强我们对肺癌生物学的认识,并为肺癌的治疗带来新的、更有效的方法。在这篇综述中,我们总结了目前关于不吸烟者肺癌的知识体系。